AUTHORS
Amrita Goyal-O'Leary, MD, Kwang Wooahn, PhD2, Tiening Chen, MS3, Jinalben Patel, MPH, BDS4, Cameron J. Turtle5, Craig Sauter, MD6, Alex Francisco Herrera, MD7, Mazyar Shadman, MD, MPH8, Francine Foss, MD9, Corey Cutler, MD,FRCPC,MPH10, Mehdi Hamadani, MD11, Peter Riedell, MD12, Elif Yilmaz, MD13
AFFILIATIONS
1 University of Minnesota, MINNEAPOLIS, Minnesota, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States, The University of Sydney, Sydney, New South Wales, Australia
6 Memorial Sloan Kettering, New York, New York, United States
7 City of Hope, Duarte, California, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States
9 Yale University School of Medicine, New Haven, Connecticut, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 University of Chicago, Chicago, Illinois, United States
13 University of Texas Southwestern Medical Center, Saint Paul, Minnesota, United States
ABSTRACT
Introduction: Advanced-stage/progressive mycosis fungoides (MF) and Sezary syndrome (SS) carry a poor prognosis. Allogeneic hematopoietic cell transplant (alloHCT) is the only potentially curative modality, but outcome data are limited.
Methods: We analyzed 517 adult patients (pts) receiving first alloHCT for MF (n=340) or SS (n=177) reported to the CIBMTR from 2008-2024. The primary endpoint was overall survival (OS). Secondary endpoints were incidence of acute and chronic graft-versus-host disease (aGVHD, cGVHD), non-relapse mortality (NRM), relapse/progression; progression free survival (PFS); GVHD/relapse-free survival (GRFS; absence of grade [gr.] 3-4 aGVHD, moderate/severe [mod/sev] cGVHD, relapse, or death); cause of death. Disease status at alloHCT was complete remission (CR), partial remission (PR), or chemoresistant/untreated (non-CR/PR). Total skin electron beam therapy (TSEBT) ≤ 120 days before alloHCT was considered transplant directed.
Results: Median age at alloHCT was 55.7 years (yrs, range 19.9-77.3); 60.5% were male; 64.6% were White, and 18.4% were Black. Median follow-up was 59.5 months (mo, range, 3.3-173.2). AlloHCT was >12 mo from diagnosis in 85.3%, and of 250 pts with prior lines of therapy reported, 80.8% had 3 or more.
Peripheral blood grafts were used in 94.4%; donors were matched related (31.3%), matched unrelated (51.8%), and haploidentical (17%). Reduced intensity conditioning was used in 77.4% and commonly included fludarabine (Flu)/Melphalan (28.8%), Flu/Busulfan (15.9%), and total body irradiation (TBI)/cyclophosphamide (Cy) (15.5%). Total lymphoid irradiation was used in 11.2%, ATG in 28.6%, and alemtuzumab in 4.4%. GVHD prophylaxis included calcineurin inhibitor (CNI)/methotrexate (40%), post-transplant Cy (27.7%), or CNI/mycophenolate (23.4%).
For all pts, the 3-yr OS and PFS were 59.1% (95% CI, 54.4-63.7%) and 32% (27.8-36.5%). The 3-yr incidence of relapse/progression was 49.9% (45.3-54.4%) with a 3-yr NRM of 18.1% (14.7-21.7%). Gr. 2-4 aGVHD incidence at 6 mo was 32.2% (27.9-36.7%). cGVHD incidence at 3-yrs was 47.7% (43.1-52.4%) with Mod/sev cGVHD 24.9% (21.1-29%). GFRS at 3 yrs was 23.8% (19.9-27.9%).
Disease control was similar for MF and SS (3-yr OS 58.5% vs 60.2%; PFS 29.1% vs 37.5%; relapse/progression 50.7% vs 41.1%). Toxicity was likewise similar (3-yr NRM 16.6% vs 17.4%; 6 mo Gr. 2-4 aGVHD 32% vs 32.7%; 3-yr cGVHD 46% vs 50.9% with Mod/sev cGVHD 25.4% vs 23.9%; 3-yr GFRS 17.9% vs 22%).
At the time of alloHCT, 24.6% of pts were in CR (n=127), 48.5% in PR (n=251), and 24.6% non-CR/PR (n=127). There was no difference in OS based on disease status (p=0.136). PFS at 3 yrs was 34.3% for pts in CR/PR vs. 23.9% for non-CR/PR (p=0.014). There was no significant difference in OS or PFS between pts in CR vs. PR.
Of 263 pts with data on mogamulizumab (moga) exposure prior to alloHCT, 43 received moga. Moga use was associated with higher 6-mo gr. 2-4 aGVHD (53.5% vs. 36.7%, p = 0.022) and 3-yr mod/sev cGVHD (44.5% vs. 28.1%, p=0.028). TSEBT exposure status was known in 193 pts: 45 received TSEBT ≤ 120 days prior to alloHCT, 33 received it >120 days prior, 115 had no TSEBT. Three-yr OS and PFS for pts with TSEBT <= 120 days prior to alloHCT vs. no TSEBT were 52.3% (34.5-69.8%) vs. 50.8% (40.9-60.8%; p=0.626) and 31.8% (16.2-49.7%) vs 26.5% (18.2-35.7%; p=0.373). The most frequent causes of death (n=234) were recurrent/persistent MF/SS (n=111, 47.4%), infection (n=31, 13.2%), and GVHD (n=24, 10.2%).
Conclusion: In this large contemporary registry cohort, alloHCT provided durable disease control in a subset of pts with MF/SS with 59% of pts alive and nearly 1/3 progression-free at 3-years. Disease status at alloHCT influenced PFS, with superior PFS in pts transplanted in CR/PR, whereas OS did not differ by disease status or between CR and PR, suggesting that a deeper remission may not be a prerequisite for alloHCT. Relapse/progression was common (50%) and the leading cause of death; strategies to reduce relapse, including post-HCT maintenance and pre-emptive intervention, warrant prospective study.
DISCLOSURES
Amrita Goyal-O'Leary, MD: No relevant conflicts of interest to declare.